DSP, a contract research organization (CRO) focusing on reproductive endocrinology and infertility studies, has conducted 80% of all infertility studies in the US over the past 15 years, while Health Decisions has conducted more than 140 clinical trials in women’s health indications, according to the companies
The partnership will combine DSP’s experience with clinical, project, and site management with Health Decision’s biostatistics and data management capabilities.
DSP will also gain access to Health Decisions’ agreements with multiple proprietary eDC platforms and medical writing services.
A spokesperson of Health Decisions told us that the partners aim to provide “extensive experience and expert support in all areas of clinical research” to companies developing interventional and medical device assets in fertility and infertility.
According to Health Decision’s CEO, Patrick Phillips, the therapeutic and operational solutions that will result from the partnership will benefit patients and industry stakeholders alike.
Speaking about the field of infertility research, the spokesperson said: “Our teams understand the complexities of designing trials in this indication and the differences between female and male study participants.”
“Women are motivated differently and have different concerns,” the spokesperson noted, adding that the companies are adept at navigating the challenges that exist when conducting research in this area.
“In addition, our relationships with an extensive network of women’s health sites can lead to easier site engagement and more efficient study start-up,” they said.
